Skip to Main Content

SAN FRANCISCO — Agios Pharmaceuticals intends to double the number of approved medicines it sells from two to four within the next six years, while also expanding into new indications and deepening its pipeline by another two programs.

The new Agios (AGIO) strategic plan — including a mandate to trim financial losses and become cash-flow positive — was announced Sunday ahead of a presentation by CEO Jackie Fouse on Monday morning at the J.P. Morgan Healthcare Conference.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED